Superior Activity of Fusion Protein scFvRit:sFasL over Cotreatment with Rituximab and Fas Agonists
Edwin Bremer(University Medical Center Groningen), Wijnand Helfrich(University Medical Center Groningen), Bram ten Cate(University Medical Center Groningen), Harald Wajant(Universitätsklinikum Würzburg), Julia Stieglmaier(Amgen (Germany)), Douwe F. Samplonius(University Medical Center Groningen), Georg H. Fey(Friedrich-Alexander-Universität Erlangen-Nürnberg), Nicole Mueller(University of Würzburg), Martine E.D. Chamuleau(Hovon), Alja J. Stel(University Medical Center Groningen), Arjan A. van de Loosdrecht(Dutch Cancer Society)
Cited by 46
Related Papers
Tumor necrosis factor signaling
|Cell Death and Differentiation|2003|2.4k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714